Pharma


  • dna helix hands
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    As gene therapies falter on the market, this biopharma is aiming to defy the odds

    After a strong launch for its cancer gene therapy, Ferring Pharmaceuticals is setting the stage for long-term growth.

    By Aug. 8, 2025
  • Arun Krishna, AstraZeneca
    Image attribution tooltip
    Permission granted by AstraZeneca
    Image attribution tooltip
    Q&A

    Inside AstraZeneca’s long-game strategy in lung cancer

    New long-term results for Tagrisso in EGFR-mutated non-small cell lung cancer showcase a precision approach the company has honed for decades.

    By Aug. 7, 2025
  • rare disease ribbon Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Rare diseases

    As drug developers find promise in the rare diseases, deals and treatments are on the rise

    By PharmaVoice staff
  • Trump budget bill
    Image attribution tooltip
    Andrew Harnik via Getty Images
    Image attribution tooltip

    PBM reform was dropped from Trump’s spending bill. It could have saved billions.

    The Senate nixed a provision to “delink” drug list prices from compensation for PBMs and other drug middlemen days before its passage.

    By Alexandra Pecci • Aug. 6, 2025
  • A man in a collared shirt poses for a photograph.
    Image attribution tooltip
    Permission granted by Vertex Pharmaceuticals
    Image attribution tooltip

    David Altshuler, geneticist who helped transform Vertex, to retire next year

    Since becoming Vertex's top scientist in 2015, Altshuler has helped the company become an industry powerhouse. He’ll depart next year in a “planned transition.”

    By Ben Fidler • Aug. 5, 2025
  • Stephane Bancel, Moderna
    Image attribution tooltip
    Chip Somodevilla / Staff via Getty Images
    Image attribution tooltip

    Let’s make a deal? Big Pharma execs express varying views on their M&A future

    Pharma executives are keeping their eyes open for dealmaking opportunities as every company has its own battles to fight.

    By Aug. 5, 2025
  • Medicine pill on 100 dollar banknote background
    Image attribution tooltip
    stock via Getty Images
    Image attribution tooltip

    Drugmakers score policy win in a prolonged fight against 340B

    A new pilot program from HHS would alter the contentious 340B pricing program by swapping traditional upfront drug discounts for rebates.

    By Aug. 4, 2025
  • A wall showing a Merck & Co. logo in Kenilworth, New Jersey
    Image attribution tooltip
    Courtesy of Merck & Co.
    Image attribution tooltip

    Merck & Co. assembles an Alzheimer’s comeback with a next-gen precision focus

    With two molecules in mid-stage trials, the pharma giant is taking another swing at the difficult disease with a greater understanding of its drivers.

    By Aug. 1, 2025
  • Mike Doustdar
    Image attribution tooltip
    Permission granted by Novo Nordisk
    Image attribution tooltip

    C-suite shuffles ripple through pharma

    Novo Nordisk, Kenvue and Jazz Pharmaceuticals announced changes at the top this month.

    By July 31, 2025
  • A smiling portrait of Vinay Prasad, the director of CBER, set against a sparkling light background.
    Image attribution tooltip
    Retrieved from Vinay Prasad on May 08, 2025
    Image attribution tooltip

    Dr. Vinay Prasad, controversial FDA official, abruptly departs agency

    Prasad's exit ends a tumultuous tenure during which he led a reworking of agency guidelines on COVID vaccines and his office got embroiled in controversy over a Duchenne gene therapy.

    By Ben Fidler • July 30, 2025
  • A sign with the Roche logo stands in front of a tall building.
    Image attribution tooltip
    Permission granted by Roche
    Image attribution tooltip

    Roche pushes ahead with late-comer strategy in obesity

    The Swiss pharma company announced several updates to its obesity portfolio in its latest earnings report.

    By July 30, 2025
  • Keytruda, Merck
    Image attribution tooltip
    Permission granted by Merck & Co.
    Image attribution tooltip

    Could bispecifics unseat Keytruda from its oncology throne?

    Signals suggest the drugs could improve on the standard of care, but the market may not make it easy for another megablockbuster to rise to the top.

    By Kelly Bilodeau • July 28, 2025
  • Lab bench
    Image attribution tooltip
    E+ via Getty Images
    Image attribution tooltip

    From the bench: Researchers make NIH-funded preclinical strides in mRNA and obesity

    The studies are contributing preclinical advances for some of the world’s biggest blockbusters.

    By July 25, 2025
  • dollars syringe
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Pharma’s turbo spending spree on US manufacturing

    The industry’s push to expand American drug production isn’t abating as threats of tariffs loom.

    By July 24, 2025
  • BMS corporate sign
    Image attribution tooltip
    Courtesy of BMS
    Image attribution tooltip

    How Bristol Myers Squibb uses AI to validate drugs before they’re even in the lab

    The company’s AI approach allows molecule candidates to be vetted for efficacy and other properties early in development.

    By Alexandra Pecci • July 24, 2025
  • The logo of the Food and Drug Administration is seen in a close-up view of the agency's website.
    Image attribution tooltip
    Mario Guti via Getty Images
    Image attribution tooltip

    Who is Dr. George Tidmarsh, the new director of CDER?

    Despite past criticism of public health policies, Tidmarsh recently praised the FDA and said he’ll focus on boosting review efficiencies.

    By Meagan Parrish and Michael Gibney • July 23, 2025
  • A sign spelling Novartis hangs on the side of a building.
    Image attribution tooltip
    Sedat Suna via Getty Images
    Image attribution tooltip

    Novartis’ Zolgensma sales fall again as gene therapy market woes persist

    Novartis has seen sales decline in a difficult gene therapy market. Is there hope on the horizon?

    By July 22, 2025
  • Large letters spelling Amgen are seen by a wall
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    3 major patent losses this year — and a key strategy to fill the gaps

    Despite promising pipelines, most new launches are missing sales targets, forcing pharmas to rethink sales strategies.

    By Kelly Bilodeau • July 21, 2025
  • Pill gavel
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Why FDA’s CRL release could open the door to lawsuits against pharma

    In a push for “radical transparency” the FDA released 200 CRLs for drugs that were later approved — some of which are now public for the first time.

    By July 18, 2025
  • An exterior shot of the johnson and johnson logo in red outside the company's headquarters
    Image attribution tooltip
    Mario Tama / Staff via Getty Images
    Image attribution tooltip

    J&J accelerates past Stelara’s fall with better-than-expected portfolio growth

    Stelara is faltering due to biosimilar entries, but J&J execs demonstrate they were ready to fill the gap all along.

    By July 17, 2025
  • Chinese flag with lot of medical pills isolated on black background
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    FDA invites more data from abroad — with a wary eye on China

    The FDA approved four drugs last year without any U.S. trial participants, but has maintained a tougher stance on China, even as it grows into an R&D powerhouse.

    By July 16, 2025
  • Capsule with hand cursor on yellow background
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A

    Need a DTC platform? Here’s how one company built its own.

    Currax Pharmaceuticals was ahead of the curve when it set up a direct access platform for its obesity med. 

    By July 14, 2025
  • A low stone wall partially obscured by long grass bears a Merck & Co. logo
    Image attribution tooltip
    Jason Doiy via Getty Images
    Image attribution tooltip

    With Verona deal, Merck wagers on strength of lung drug’s patents

    The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make good on the deal, other secondary patents will need to hold up.

    By Jonathan Gardner • July 11, 2025
  • Pill drug money balance
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Pricing watchdog will take on the rising cost of drugs at launch

    ICER’s upcoming report could shed light on how the launch price of newly approved drugs affects overall cost and access from a patient perspective.

    By July 10, 2025
  • President Donald Trump speaks during a cabinet meeting at the White House on July 8, 2025, in Washington, D.C.
    Image attribution tooltip
    Andrew Harnik via Getty Images
    Image attribution tooltip

    Trump says ‘very high’ pharmaceutical tariffs coming soon

    While Trump indicated drug levies would be as high as 200%, he added that pharma firms would first be given time to bring manufacturing back to the U.S.

    By Philip Neuffer • July 9, 2025
  • Laboratory bottles with blue content and a syringe
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    First 90 Days

    As its cancer vaccine moves through the clinic, Transgene sets sights on manufacturing

    Simone Steiner recently joined the French company to set the stage for launch.  

    By July 9, 2025